Skip to main content
. 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339

Figure 1.

Figure 1

Impact of hyperimmune convalescent plasma (A) anti-SARS-CoV-2 monoclonal antiboby (B) and hyperimmune convalescent plasma plus anti-SARS-CoV-2 monoclonal antibody (C) therapy on immune parameters and specific T cell response in peripheral blood before and after treatment.